vinorelbine + firmonertinib

vinorelbine + AST2818 (vinorelbine + firmonertinib) is an all-oral combination regimen consisting of the semi-synthetic vinca alkaloid vinorelbine and the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) firmonertinib (AST2818). Vinorelbine acts as a microtubule inhibitor, disrupting mitotic spindle assembly to induce cell cycle arrest and apoptosis. Firmonertinib is an irreversible, covalent inhibitor that selectively targets both EGFR-sensitizing mutations (such as exon 19 deletions and L858R) and the T790M resistance mutation while sparing wild-type EGFR. This combination is being evaluated as a first-line treatment for patients with refractory EGFR-mutated advanced non-small cell lung cancer (NSCLC), particularly those with M1c2 disease or elevated PD-L1 expression, to provide a convenient, tolerable, and effective chemotherapy-sparing oral regimen.

Other names

oral vinorelbine + firmonertiniboral vinorelbine + furmonertinibvinorelbine + AST-2818vinorelbine + AST2818vinorelbine + alflutinibvinorelbine + firmonertinibvinorelbine + furmonertinibvinorelbine plus AST-2818vinorelbine plus AST2818vinorelbine plus alflutinibvinorelbine plus firmonertinibvinorelbine plus furmonertinib